Research progress on roxadustat treatment for renal anemia

doi:10.16352/j.issn.1001-6325.2022.09.1449

Abstract

Abstract: Renal anemia is an independent risk factor for progression of chronic kidney disease (CKD).Roxadustat, a novel medicine for renal anemia, utilizes the body's native response to hypoxia for activating the hypoxia-induced signaling pathway, regulating endogenous erythropoietin(EPO) production and improving iron metabolism, so effectively corrects hemoglobin level and comprehensively regulates erythropoiesis.

Key words: roxadustat, renal anemia, prolyl hydroxylase inhibitor, hypoxia-inducible factor, chronic kidney disease

CLC Number:

HU Bao-li, HU Bin. Research progress on roxadustat treatment for renal anemia[J]. Basic & Clinical Medicine, 2022, 42(9): 1449-1453.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.09.1449

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I9/1449

References 20

[1]	Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories[J]. Lancet, 2018,392:2052-2090.
[2]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012,379:815-822.
[3]	Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anemia[J]. BMC Nephrol,2016,17:97. doi: 10.1186/s12882-016-0312-9.
[4]	束金莲, 李贺, 姚少峰, 等. 初始血液透析患者贫血的相关危险因素回顾性研究[J]. 中国现代医学杂志, 2020:1-9.
[5]	Ni Z, Jin H, Jiang G, et al. A telemedicine-based registration system for the management of renal anemia in patients on maintenance hemodialysis: multicenter study[J]. J Med Inter Res, 2019,21:e13168.doi: 10.2196/13168.
[6]	McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease[J]. Am J Nephrol, 2013,37:549-58.
[7]	Semenza GL. HIF-1 and mechanisms of hypoxia sensing[Z]. England: Elsevier Ltd, 2001,13: 167-171.
[8]	Wang K, Wu J, Xu J, et al. Correction of anemia in chronic kidney disease with angelica sinensis polysac-charide via restoring EPO production and improving iron availability[J]. Front Pharmacol, 2018,9:803. doi:10.3389/fphar.2018.00803.
[9]	Schwartz AJ, Das NK, Ramakrishnan SK, et al. Hepatic hepcidin/intestinal HIF-2alpha axis maintains iron absorption during iron deficiency and overload[J]. J Clin Invest, 2019,129:336-348.
[10]	Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019,381:1011-1022.
[11]	Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator(darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan[J]. J Am Soc Nephrol, 2020,31:1628-1639.
[12]	Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis[J]. Nephrol Dial Transplant, 2021.doi: 10.1093/ndt/gfab051.
[13]	Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients[J]. Kidney Int Rep, 2021,6:624-635.
[14]	Shutov E, Sulowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)[J]. Nephrol Dial Transplant, 2021.doi: 10.1093/ndt/gfab057.
[15]	Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study[J]. J Am Soc Nephrol, 2021,32:737-755.
[16]	Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019,381:1001-1010.
[17]	Yang Q, Wang X. A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anemia[J]. Int J Clin Pract, 2021.doi: 10.1111/ijcp.14011.
[18]	Chen C, Yan S, Qiu S, et al. HIF/Ca2+/NO/ROS is critical in roxadustat treating bone fracture by stimulating the proliferation and migration of BMSCs[J].Life Sci,2021.doi: 10.1016/j.lfs.2020.118684.
[19]	Morris DR, Qu Y, Agrawal A, et al.HIF-1α modulates core metabolism and virus replication in primary airway epithelial cells infected with respiratory syncytial virus[J]. Viruses, 2020,12:1088. doi: 10.3390/v12101088.
[20]	Zhang X, Zhang Y, Wang P, et al. Adipocyte hypoxia-inducible factor 2alpha suppresses atherosclerosis by promoting adipose ceramide catabolism[J]. Cell Metab, 2019,30:937-951.